AIDSinfo - Drug Details

A Service of The U.S. Department of Health
and Human Services

Antiretroviral Drugs

Fusion Inhibitors

Enfuvirtide (Fuzeon, T-20)

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Delavirdine (Rescriptor)

Efavirenz (Sustiva)

Nevirapine (Viramune)

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Abacavir (Ziagen)

Abacavir + Lamivudine (Epzicom)

Abacavir+Lamivudine+Zidovudine (Trizivir)

Didanosine (Videx, ddI)

Emtricitabine (Emtriva, FTC)

Emtricitabine + Tenofovir DF (Truvada)

Lamivudine (Epivir, 3TC)

Lamivudine+Zidovudine (Combivir)

Stavudine (Zerit, d4T)

Tenofovir DF (Viread)

Zalcitabine (Hivid, ddC)

Zidovudine (Retrovir, AZT, ZDV)

Protease Inhibitors (PIs)

Amprenavir (Agenerase)

Atazanavir (Reyataz)

Fosamprenavir (Lexiva, 908)

Indinavir (Crixivan)

Lopinavir+Ritonavir (Kaletra)

Nelfinavir (Viracept)

Ritonavir (Norvir)

Saquinavir (Fortovase, Invirase)

Home > Drugs > Sustiva

Efavirenz (Sustiva)

Generic Name: Efavirenz
Brand Name: Sustiva

Efavirenz, also known as Sustiva, is a type of antiretroviral drug called a nonnucleoside reverse transcriptase inhibitor (NNRTI). This class of medicines blocks reverse transcriptase, an enzyme (protein that helps chemical reactions) that HIV needs to make more copies of itself.

AIDSinfo Drug Record for Efavirenz

Search the Drug Database

Guidelines References to Efavirenz

	Adult and Adolescent Guidelines
	Table 12a: Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection in Antiretroviral Naïve Patients
	Table 12b: Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
	Table 13: Antiretroviral Dosing Recommendations for Patients with Renal or Hepatic Dysfunction
	Table 14: Antiretroviral Regimens or Components That Should Not Be Offered At Any Time
	Table 16: Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
	Table 20: Drugs That Should Not Be Used With PI or NNRTI Antiretrovirals
	Table 21: Drug Interactions Between Antiretrovirals and Other Drugs: PIs, NNRTIs, and NRTIs
	Table 22b: Drug Effects on Blood Concentration of NNRTIs
	Table 23: HIV-Related Drugs with Overlapping Toxicities
	Table 27: Suggested Minimum Target Trough Concentrations for Persons with Wild-Type HIV-1
	Table 30: Preclinical and Clinical Data Concerning the Use of Antiretrovirals During Pregnancy
	Pediatric Guidelines
	Appendix: Characteristics of Available Antiretroviral Drugs
	NNRTI Drugs - Pediatrics
	Supplement: Pediatric Antiretroviral Drug Information
	Table 11: Recommended Antiretroviral Regimens for Initial Therapy for HIV Infection in Children
	Table 9: Advantages and Disadvantages of NNRTI for Use in Highly Active Antiretroviral Combination Regimens
	Perinatal Guidelines
	NNRTI Drugs - Perinatal
	Table 2: Preclinical and Clinical Data Relevant to the Use of Antiretrovirals During Pregnancy
	Table 3: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

Efavirenz News

	Label Changes for Sustiva - August 2004
	more...

More About Efavirenz

	AIDSinfo Drug Record for Efavirenz
	MEDLINEplus Fact Sheet on Efavirenz
	Clinical Trials Using Efavirenz
	Literature Citations for Efavirenz
	more...